2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6210 The association between hereditary hemorrhagic telangiectasia and skin cancer: A retrospective cohort study

Ruhi Kanwar, MD, Sam Schepps, MD2, Georgiana McTigue, BA3, Nancy Anabaraonye, BA4, Sarah Schultz, BA5, Brianna Spiegel, BS6, Kevin Fettel, MSc7, Vinod E Nambudiri, MD MBA MPH EdM8
1 Brigham & Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 University of Maryland School of Medicine, Baltimore, Maryland, United States
3 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
4 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
5 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Medical College of Georgia, Athens, Georgia, United States
6 Boston University School of Medicine, Boston, Massachusetts, United States, Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States
7 Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Brigham & Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dermatology Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare inherited autosomal dominant vascular disorder characterized by abnormal blood vessel formation. It manifests with mucocutaneous telangiectasias, recurrent epistaxis, and arteriovenous malformations in various organs. (Kluger et al. Melanoma Res. 2007) (Hosman et al, Orphanet J Rare Disease, 2013) The genetic condition is a result of loss-of-function in genes relating to the TGF-B family, critical to angiogenesis and vascular modeling. Recent research has looked into the potential association of HHT with malignancy – primarily breast, colorectal, lung, and prostate (Duarte et al, J Cancer Res Clin Onc, 2017); however, there the relationship between HHT and skin cancer remains unclear and without available evidence. There have been occasional malignant melanoma case reports, including fatal neoplasm with HHT. (Kluger et al. Melanoma Res. 2007) With chronic inflammation, skin manifestations, and TGF-B’s role as a growth inhibitor for keratinocytes (Ke et al, J Invest Derm, 2022), investigation into the association between HHT and skin cancer is warranted. Thus, this retrospective cohort study aimed to assess the risk of skin cancer in patients with HHT.

The Brigham and Women’s Hospital and Massachusetts General Hospital patient registry was queried from 1979 to March 2025 for charts with HHT in any clinical documentation. This exposed cohort was matched by age, sex, and race 1:1 to patients without HHT to produce the unexposed cohort. Subsequent chart review was conducted and of 1753 patients, 777 patients were included with HHT. Of the matched unexposed patients, 1402 patients were included without HHT. Charts lacking appropriate HHT status or clinical encounter data were excluded. Multivariable logistic regression analysis (adjusted for age, sex, smoking history, and family history of skin cancer) was conducted using R.

The majority of patients with HHT were female (58.4%), white (87.5%), and non-Hispanic (83.4%). A significant positive association was found between HHT and skin cancer diagnosis (adjusted odds ratio 1.381, 95% CI 1.012-1.885, p=0.042). Specifically, there was an increased risk of keratinocyte carcinomas – either basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) (adjusted odds ratio 1.406, 95% CI 1.018-1.943, p=0.039). In subgroup analysis amongst patients with HHT, having a blood transfusion need (of 3 or more), did not increase risk of skin cancer compared to HHT patients who did not require blood transfusions (adjusted odds ratio 0.635, 95% CI 0.352-1.146, p=0.134). Of the patients with HHT, 7 patients had a liver transplantation. Due to limited size, a subgroup analysis by liver transplantation status was unable to be performed amongst the HHT cohort.

Our study suggests that patients with HHT may have an increased risk of skin cancer and keratinocyte carcinomas. Our study’s is limited by its retrospective design, sample size, and use of one health care system. Overall, this study provides the first retrospective analysis of association. Future studies are needed to investigate skin cancer survival outcomes and staging with HHT pathophysiology, given that altered vessel integrity has been suggested to affect cancer progression. (Duarte et al, Cancer Epidemiol Biomarkers Prev, 2014) Additionally, studies such as prospective or larger retrospective data are needed to better understand the overall risk.
Ruhi Kanwar, MD: No relevant conflicts of interest to declare.